CRIS Current Research Information System

PALARETI, GUALTIERO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.957
AS - Asia 6.096
EU - Europa 4.407
Continente sconosciuto - Info sul continente non disponibili 332
AF - Africa 328
SA - Sud America 323
OC - Oceania 46
Totale 19.489
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.812
SG - Singapore 1.920
CN - Cina 1.583
VN - Vietnam 1.283
GB - Regno Unito 1.211
DE - Germania 649
IT - Italia 547
SE - Svezia 384
HK - Hong Kong 372
FR - Francia 345
UA - Ucraina 308
IN - India 298
RU - Federazione Russa 267
BR - Brasile 235
IE - Irlanda 166
NL - Olanda 161
JP - Giappone 126
KR - Corea 113
ZA - Sudafrica 113
BD - Bangladesh 96
FI - Finlandia 91
EE - Estonia 83
CA - Canada 74
SC - Seychelles 67
PH - Filippine 49
CI - Costa d'Avorio 47
ID - Indonesia 47
MX - Messico 45
AR - Argentina 34
JO - Giordania 34
TG - Togo 33
CH - Svizzera 30
AU - Australia 28
AT - Austria 27
EG - Egitto 27
TH - Thailandia 24
BE - Belgio 22
CZ - Repubblica Ceca 22
IQ - Iraq 22
PL - Polonia 21
GR - Grecia 18
NZ - Nuova Zelanda 18
PK - Pakistan 18
SA - Arabia Saudita 17
TR - Turchia 15
TW - Taiwan 15
CO - Colombia 14
BG - Bulgaria 13
MY - Malesia 13
CL - Cile 10
ES - Italia 10
MA - Marocco 10
UZ - Uzbekistan 10
KE - Kenya 8
PY - Paraguay 8
JM - Giamaica 7
LB - Libano 6
PE - Perù 6
PS - Palestinian Territory 6
RO - Romania 6
UY - Uruguay 6
AL - Albania 5
CR - Costa Rica 5
DZ - Algeria 5
OM - Oman 5
EC - Ecuador 4
LT - Lituania 4
TN - Tunisia 4
DK - Danimarca 3
DO - Repubblica Dominicana 3
GT - Guatemala 3
HR - Croazia 3
IL - Israele 3
IR - Iran 3
NG - Nigeria 3
AZ - Azerbaigian 2
BH - Bahrain 2
BO - Bolivia 2
GY - Guiana 2
HU - Ungheria 2
KH - Cambogia 2
KZ - Kazakistan 2
LK - Sri Lanka 2
ML - Mali 2
MM - Myanmar 2
NO - Norvegia 2
NP - Nepal 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
TT - Trinidad e Tobago 2
TZ - Tanzania 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
BZ - Belize 1
ET - Etiopia 1
GP - Guadalupe 1
Totale 19.146
Salva come PNG Salva come JPEG
Città #
Singapore 1.319
Southend 1.025
Fairfield 854
Ashburn 640
Santa Clara 558
San Jose 393
Woodbridge 383
Chandler 376
Seattle 375
Houston 371
Wilmington 366
Hong Kong 355
Cambridge 310
Princeton 277
Hefei 261
Ho Chi Minh City 258
Dong Ket 238
Ann Arbor 214
Hanoi 209
Beijing 205
Jacksonville 204
Council Bluffs 197
Boardman 178
Dublin 162
Lauterbourg 133
Nanjing 122
Westminster 111
Tokyo 109
Los Angeles 101
Padova 101
Berlin 91
Seoul 90
Helsinki 78
New York 75
Dallas 70
Buffalo 65
Bologna 64
Jinan 62
San Diego 56
Shenyang 55
Milan 54
Turin 48
Da Nang 47
Abidjan 46
Saint Petersburg 45
Hebei 41
Changsha 39
Mülheim 39
Nanchang 37
Redondo Beach 36
Chicago 35
Dearborn 35
Munich 35
São Paulo 35
Amman 34
Frankfurt am Main 34
Lomé 33
The Dalles 30
Des Moines 28
Redmond 27
Can Tho 26
Shanghai 25
Zhengzhou 25
Bengaluru 23
Bremen 23
Mahé 23
Bern 22
London 22
Phoenix 22
Rome 22
Brussels 21
Moscow 21
San Francisco 21
Tianjin 21
Haiphong 20
Montreal 20
Al Mansurah 19
Hangzhou 19
Mexico City 19
Verona 19
Guangzhou 18
Toronto 18
Johannesburg 17
Lanzhou 17
Jakarta 15
Kunming 15
Norwalk 15
Orem 15
Taizhou 15
Bangkok 14
Brooklyn 14
Bühl 14
Medford 14
Cesena 13
Denver 13
Nuremberg 13
Vienna 13
Baghdad 12
Biên Hòa 12
Cebu City 12
Totale 12.591
Salva come PNG Salva come JPEG
Nome #
D-dimer in diagnosis and prevention of venous thrombosis: recent advances and their practical implications 594
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum). 314
Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta-analysis 268
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. 259
Thrombotic events after vaccination for covid-19 in Italy: a report from the Italian society on thrombosis and haemostasis registry 255
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. 213
Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke. 205
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. 205
Hereditary thrombophilia and fetal loss: a prospective follow-up study. 201
Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. 200
Age and gender specific cut-off values to improve the performance of D: -dimer assays to predict the risk of venous thromboembolism recurrence. 195
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis 193
A new rapid bedside assay for D-dimer measurement (Simplify D-dimer) in the diagnostic work-up for deep vein thrombosis. 192
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal. 192
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study 186
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. 184
D-Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal. 183
Comparison between different D-Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study 180
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels. 179
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism. 176
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study 175
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register 168
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study 167
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome 165
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. 165
High plasma levels of factor VIII and risk of recurrence of venous thromboembolism 165
Familial thrombophilia and lifetime risk of venous thrombosis 164
Bridging therapy in oral anticoagulated patients: focusing on how to do it. 164
Analysis of agreement between duplex ultrasound scanning and arteriography in patients with lower limb artery disease 163
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 162
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting 162
Incidence and clinical outcomes of heparin-induced thrombocytopenia: 11 year experience in a tertiary care university hospital 161
Diagnosis of deep vein thrombosis. 159
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 159
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis. 159
A multicentre randomised clinical endpoint study of PARMA 5 computer-assisted oral anticoagulant dosage. 158
An international multicenter randomized study of computer-assisted oral anticoagulant dosage vs. medical staff dosage. 157
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in hemodialysis patients 155
External validation of the DASH prediction rule: a retrospective cohort study 155
D-dimer testing and venous thromboembolism: four view points 154
D-dimer and reduced dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study. 153
Lo studio BAFTA [The BAFTA study] 153
Predictors of psychological state after genetic testing for inherited thrombophilia 152
HemosIL D-dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study. 150
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study 150
Fibrin D-dimer testing for venous and arterial thrombotic disease 147
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis. 147
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: The Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study 147
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: A prospective multicenter study 147
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long-term recurrence. 144
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: the blind, prospective CALTHRO study. 144
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the Prolong extension study. 144
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. 143
Predicting the risk of recurrence of venous thromboembolism. 142
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms 142
The prothrombin time/international normalized ratio (PT/INR) Line: derivation of local INR with commercial thromboplastins and coagulometers--two independent studies. 141
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study. 141
D-dimer and risk of venous thromboembolism recurrence: Comparison of two studies with similar designs but different laboratory and clinical results 140
Sex, age and normal post-anticoagulation D-dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension. 139
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study. 134
Warfarin anticoagulation in children made easier. 133
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. 133
VASCULAR ENDOTHELIAL DYSFUNCTION IN PRIMARY OPEN ANGLE GLAUCOMA 132
Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants 131
Inappropriate Underdosing of Direct Oral Anticoagulants in Atrial Fibrillation Patients: Results from the START2-AF Registry 130
D-dimer, oral anticoagulation, and venous thromboembolism recurrence 130
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. 130
Extended treatment for venous thromboembolism: how long is long enough? 129
Low-intensity oral anticoagulant plus low-dose aspirin during the first six months versus standard-intensity oral anticoagulant therapy after mechanical heart valve replacement: a pilot study of low-intensity warfarin and aspirin in cardiac prostheses (LIWACAP). 129
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of a portable prothrombin time monitor (COAGUCHECK) 129
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? 128
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 127
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). 127
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. 126
The negative predictive value of D-dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study). 125
The Wells rule and D-dimer for the diagnosis of isolated distal deep vein thrombosis 125
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. 124
PROFILASSI DELLA MALATTIA TROBOEMBOLICA VENOSA IN CHIRURGIA BARIATRICA: STUDIO PROSPETTICO RANDOMIZZATO DI CONFRONTO TRA DUE DIFFERENTI DOSAGGI DI PARNAPARIN 123
Recurrence rate after a first venous thrombosis in patients with familial thrombophilia 123
Risks factors for highly unstable response to oral anticoagulation: a case-control study. 123
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. 122
Venous thromboembolism in renal transplant recipients: Results of Venous thromboEmbolism in renal Transplant Recipients- Italian Study - VETRIS 122
Predictors of psychological state after genetic testing for inherited trombophilia 120
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. 120
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study 120
Psychological impact of testing for thrombophilic alterations. 120
D-dimer testing to determine the duration of anticoagulation therapy. 120
DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register 119
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register 119
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 118
Modulation of factor V levels in plasma by polymorphisms in the C2 domain. 117
Risk factors for venous thromboembolism in the elderly: results of the master registry. 117
The first ambulatory screening on thromboembolism: a multicentre, cross-sectional, observational study on risk factors for venous thromboembolism. 115
D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-Vitamin K anticoagulants 115
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism. 114
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study 114
Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). 113
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs 113
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants 113
Old and new heparins. 111
Totale 15.610
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.153
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.153
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.671 0 59 169 125 224 109 49 164 70 86 273 343
2022/20231.923 244 278 112 252 119 148 53 89 285 68 175 100
2023/2024381 30 77 37 36 30 30 23 29 12 34 18 25
2024/20252.930 66 484 150 183 763 140 179 34 65 239 114 513
2025/20265.908 359 661 577 430 758 399 528 293 931 421 307 244
2026/2027564 329 235 0 0 0 0 0 0 0 0 0 0
Totale 19.489